{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T20:49:02Z","timestamp":1757450942594,"version":"3.41.2"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Adherence to disease-modifying therapies (DMTs) in multiple sclerosis (MS) is crucial for effective treatment. Understanding the patients\u2019 perspective and identification of factors influencing adherence to treatment may allow improved disease management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This study attempted to evaluate adherence to DMTs in people with MS and explore potential patient-related factors influencing level of adherence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>121 patients with relapsing-remitting MS (90% women, aged 34.0 \u00b1 10 years participated in the online self-reported survey, which included: Adherence in Chronic Diseases scale (ACDS), Patient health questionnaire (PHQ-9) as a measure of depression, Modified Fatigue Impact Scale (MFSI), Perceived Stress Scale (PSS-10), Acceptance of Illness Scale (AIS), and a questionnaire about demographics and basic patient-reported clinical data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The ACDS results comprised between 9 and 28 points, with a mean value of 24.0 \u00b1 3.8, indicating a moderate level of adherence. Fatigue was reported by 70% of patients and the results of MFIS showed significant correlation with ACDS (R=-0.260; p=0.004) and AIS score (R=0.487; p &amp;lt;0.001). Relationships were found between the results of AIS and PHQ-9 and PSS-10 but none of them was associated with ACDS, and neither were demographic data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The adherence to treatment among MS patients is moderate and significantly associated with fatigue. Evaluating the level of adherence and the patients\u2019 psychosocial condition may contribute to personalized and optimal therapeutic approach.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1545430","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T04:10:49Z","timestamp":1750911049000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Adherence to therapeutic recommendation in relapsing-remitting multiple sclerosis patients"],"prefix":"10.3389","volume":"16","author":[{"given":"Justyna","family":"Chojdak-\u0141ukasiewicz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Ko\u0142tuniuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Sawicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Pokryszko-Dragan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: A review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult Scler"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200032","article-title":"Association of NEDA-4 with no long-term disability progression in multiple sclerosis and comparison with NEDA-3: A systematic review and meta-analysis","volume":"9","author":"Rotstein","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: A review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am J Med"},{"key":"B5","unstructured":"Sabat\u00e9\n              E\n            \n          \n          Geneva, Switzerland\n          World Health Organization\n          Adherence to Long-Term Therapies: Evidence for Action\n          \n          2003"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.5603\/pjnns.102356","article-title":"Disease modyfifying therapy in multiple sclerosis recommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society","volume":"58","author":"Ku\u0142akowska","year":"2024","journal-title":"Neurol Neurochir Pol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5603\/FC.a2016.0105","article-title":"Skala adherence w chorobach przewlek\u0142ych \u2014 nowe narz\u0119dzie do badania realizacji planu terapeutycznego","volume":"12","author":"Kubica","year":"2017","journal-title":"Folia Cardiologica"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: Validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.7224\/1537-2073.2012-019","article-title":"Psychometric properties of the modified fatigue impact scale","volume":"15","author":"Larson","year":"2013","journal-title":"Int J MS Care"},{"key":"B11","first-page":"11","article-title":"PSS 10","volume-title":"Narz\u0119dzia pomiaru stresu i radzenia sobie ze stresem","author":"Juczy\u0144ski","year":"2009"},{"key":"B12","article-title":"Skala akceptacji choroby - AIS","volume-title":"Narz\u0119dzia pomiaru w promocji i psychologii zdrowia","author":"Juczy\u0144ski","year":"2001"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S130334","article-title":"Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis","volume":"9","author":"Burks","year":"2017","journal-title":"CEOR"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-010-1253-9","article-title":"Primary medication non-adherence: analysis of 195,930 electronic prescriptions","volume":"25","author":"Fischer","year":"2010","journal-title":"J Gen Intern Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2013.19.s1.S24","article-title":"Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis","volume":"19","author":"Menzin","year":"2013","journal-title":"JMCP"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10850-w","article-title":"Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review","volume":"269","author":"Washington","year":"2021","journal-title":"J Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.15225\/PNN.2020.9.3.3","article-title":"Adherence to therapeutic recommendations in patients suffering from multiple sclerosis","volume":"9","author":"Olkiewicz","year":"2020","journal-title":"PNIN"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105727","article-title":"Barriers and strategies to medication adherence amongst people with multiple sclerosis and cognitive problems","volume":"88","author":"Thomason","year":"","journal-title":"Multiple Sclerosis Related Disord"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133279","article-title":"Adherence to disease modifying drugs among patients with multiple sclerosis in Germany: A retrospective cohort study","volume":"10","author":"Hansen","year":"2015","journal-title":"PloS One"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/JNN.0000000000000395","article-title":"Factors affecting the adherence to disease- modifying therapy in patients with multiple sclerosis","volume":"50","author":"Erbay","year":"2018","journal-title":"J Neurosci Nursing"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S187983","article-title":"Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain","volume":"13","author":"Morillo Verdugo","year":"2019","journal-title":"PPA"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S401962","article-title":"Factors associated with therapeutic adherence in multiple sclerosis in Spain","volume":"17","author":"Soria","year":"2023","journal-title":"PPA"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.15225\/PNN.2021.10.3.4","article-title":"Strategies of coping with stress and the quality of life in relation to the adherence to therapeutic recommendations in MS \u2014 Affected patients","volume":"10","author":"Ko\u0142tuniuk","year":"2021","journal-title":"PNIN"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4081\/ni.2017.6957","article-title":"Subcutaneous interferon \u03b2-1a administration by electronic auto-injector is associated with high adherence in patients with relapsing remitting multiple sclerosis in a real-life study","volume":"9","author":"J\u00e4rvinen","year":"2017","journal-title":"Neurol Int"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2016.22.12.1394","article-title":"Adherence to disease-modifying therapies for multiple sclerosis","volume":"22","author":"Higuera","year":"2016","journal-title":"J Managed Care Specialty Pharmacy"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2015.00460","article-title":"Fatigue in multiple sclerosis: neural correlates and the role of non-invasive brain stimulation","volume":"9","author":"Chalah","year":"2015","journal-title":"Front Cell Neurosci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1231321","article-title":"Management of multiple sclerosis fatigue in the digital age: from assessment to treatment","volume":"17","author":"Pinarello","year":"2023","journal-title":"Front Neurosci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-009-0096-y","article-title":"Factors that influence adherence with disease-modifying therapy in MS","volume":"256","author":"Treadaway","year":"2009","journal-title":"J Neurol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/271321","article-title":"The impact of comorbid depression on adherence to therapy for multiple sclerosis","volume":"2011","author":"Tarrants","year":"2011","journal-title":"Multiple Sclerosis Int"},{"key":"B30","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/JNN.0000000000000405","article-title":"Factors affecting the adherence to disease-modifying therapy in patients with multiple sclerosis","volume":"50","author":"Von Gaudecker","year":"2018","journal-title":"J Neurosci Nurs"},{"key":"B31","doi-asserted-by":"publisher","first-page":"175628642110310","DOI":"10.1177\/17562864211031099","article-title":"Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis","volume":"14","author":"Zanga","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.61964","article-title":"The impact of motor disability and the level of fatigue on adherence to therapeutic recommendations in patients with multiple sclerosis treated with immunomodulation","volume":"18","author":"\u015alusarz","year":"2021","journal-title":"Int J Med Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2016.11.067","article-title":"Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta- analysis","volume":"372","author":"Boeschoten","year":"2017","journal-title":"J Neurological Sci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/s41398-023-02555-7","article-title":"Depressive symptoms, anxiety and cognitive impairment: emerging evidence in multiple sclerosis","volume":"13","author":"Margoni","year":"2023","journal-title":"Transl Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","first-page":"100484","DOI":"10.1016\/j.bbih.2022.100484","article-title":"Prevalence of depression and anxiety in the different clinical forms of multiple sclerosis and associations with disability: A systematic review and meta-analysis","volume":"24","author":"Peres","year":"2022","journal-title":"Brain Behavior Immun - Health"},{"key":"B36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s41983-023-00702-x","article-title":"Relationship between disability and psychiatric outcome in multiple sclerosis patients and its determinants","volume":"59","author":"Hassan","year":"2023","journal-title":"Egypt J Neurol Psychiatry Neurosurg"},{"key":"B37","doi-asserted-by":"publisher","first-page":"205510291561227","DOI":"10.1177\/2055102915612271","article-title":"Stress and multiple sclerosis: A systematic review considering potential moderating and mediating factors and methods of assessing stress","volume":"2","author":"Briones-Buixassa","year":"2015","journal-title":"Health Psychol Open"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/68944","article-title":"The relationship between event-related potentials, stress perception and personality type in patients with multiple sclerosis without cognitive impairment: A pilot study","volume":"27","author":"Waliszewska - Pros\u00f3\u0142","year":"2018","journal-title":"Adv Clin Exp Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/RNJ.0000000000000288","article-title":"The role of disease acceptance, life satisfaction, and stress perception on the quality of life among patients with multiple sclerosis: A descriptive and correlational study","volume":"46","author":"Ko\u0142tuniuk","year":"2020","journal-title":"Rehabil Nurs"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2147\/PRBM.S310664","article-title":"The role of stress perception and coping with stress and the quality of life among multiple sclerosis patients","volume":"14","author":"Ko\u0142tuniuk","year":"2021","journal-title":"PRBM"},{"key":"B41","doi-asserted-by":"crossref","DOI":"10.15225\/PNN.2017.6.4.4","article-title":"The impact of ilness acceptance on quality of life of patients with multiple sclerosis \u2014 Preliminary study","volume":"6","author":"Rosi\u0144czuk","year":"2017","journal-title":"PNIN"},{"key":"B42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.15225\/PNN.2015.4.1.3","article-title":"The degree of illness acceptance among patients with multiple sclerosis","volume":"4","author":"Pejas-Grzybek","year":"2015","journal-title":"PNIN"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.3390\/ijerph15122678","article-title":"Biomedical variables and adaptation to disease and health-related Quality of life in Polish patients with MS","volume":"15","author":"Dymecka","year":"2018","journal-title":"IJERPH"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.30773\/pi.2019.0106","article-title":"Neuropsychiatric symptoms of multiple sclerosis: state of the art","volume":"16","author":"Silveira","year":"2019","journal-title":"Psychiatry Investig"},{"key":"B45","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/PPA.S118107","article-title":"An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease- modifying drug","volume":"11","author":"Munsell","year":"2016","journal-title":"PPA"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1545430\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T04:10:51Z","timestamp":1750911051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1545430\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2025.1545430"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1545430","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"article-number":"1545430"}}